Drug Profile

KRM II 81

Alternative Names: KRM-II-81

Latest Information Update: 28 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Wisconsin at Milwaukee
Developer RespireRx Pharmaceuticals; University of Wisconsin at Milwaukee
Class Analgesics; Antiepileptic drugs; Anxiolytics; Small molecules
Mechanism of Action GABA A receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Epilepsy; Pain

Most Recent Events

28 Apr 2026 No recent reports of development identified for preclinical development in Epilepsy in USA
28 Apr 2026 No recent reports of development identified for preclinical development in Pain in USA
19 Nov 2025 The UWM Research Foundation (UWMRF) and RespireRx Pharmaceuticals have amended and restated their patent license agreement

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com